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SHORT COMMUNICATION
Survival of classic Kaposi's sarcoma and risk of second cancer
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Summary In order to elucidate survival rates and risk of second primary cancer, we assessed 204 patients with
histologically confirmed classic Kaposi's sarcoma (KS) who were identified in 11 Italian population-based
cancer registries. One hundred and thirty-nine were men (median age 70 years) and 65 were women (median
age 72). One, 5 and 10 year survival rates were 0.92, 0.69 and 0.46 respectively. Median survival was 9.4 years
(i.e. not different from the Italian general population of the same sex and age). Survival did not vary according
to sex and tumour site (i.e. lower limbs only or other). Eleven second primary cancers, including two lung and
two kidney cancers, were reported after KS diagnosis (not different from the expected number).
Keywords: classic Kaposi's sarcoma; survival; second primary tumour
Patients with HIV-associated Kaposi's sarcoma (KS) show a
poor survival (median survival 15 months; Lundgren et al.,
1995), mainly because of the underlying severe immunodefi-
ciency. Conversely, classic KS typically runs a chronic course,
with patients surviving an average of 10- 15 years before
dying from unrelated causes (Tappero et al., 1993). Follow-
up studies of patients with non-AIDS-associated KS are,
however, few (Templeton and Bhana, 1975; Safai et al., 1980;
Garcia et al., 1989; Biggar et al., 1994; Brambilla et al.,
1994). An excess of second primary malignancies, particularly
non-Hodgkin's lymphomas (NHLs), has been reported (Safai
et al., 1980), but this seems to be substantially less marked in
classic and African-type KS than in HIV-associated KS
(Dictor and Attewell, 1988; Garcia et al., 1989; Biggar et al.,
1994; Stein et al., 1994).
Materials and methods
In order to elucidate survival rates and risk of second
primary cancer, we assessed a series of 204 patients with
classic KS that was identified in the context of a case-
control study on risk factors for KS onset (Geddes et al.,
1995). Eligible case subjects were aged 50 years or older and
had histologically confirmed classic KS in the period 1976-
91, according to 1 of 11 population-based Italian cancer
registries. To exclude HIV-related KS, several checks were
made, including assessment of medical records and death
certificates and anonymous linkage of KS cases with the
mandatory records of all AIDS cases in Italy (Geddes et al.,
1995). This led to the exclusion of 2 out of 206 initial KS
patients. Occurrence of death or second primary cancer(s)
was assessed using the same cancer registry data during a
total of 1409 person-years of follow-up.
We computed both observed Kaplan-Meier and relative
survival curves (Parkin and Hakulinen, 1991). Annual
expected probability of death and life expectancy for the
general Italian population of the same sex and age groups
were used for this purpose. Hazard ratios (HRs) of death and
corresponding 95% confidence intervals (CIs) according to
sex, age group and disease site(s) were determined by means
of the Cox method.
Results
Of a total of 204 KS patients, 139 were men (median age 70
years, range 50-90) and 65 women (median age 72 years,
range 50-93) (Table I). Lower limbs were the only disease
site in 122 (60%) patients. KS was restricted to lower limbs
significantly less often in men (74/138) than in women (48/
65) (X2i = 7.54; P=0.006). In addition there was a non-
significant trend towards an increase in lower limb lesions
only with increasing age (25/51 at age 50-64 years, 53/85 at
65-74 years and 44/68 at age 75 or more, X21 trend=2.75;
P=0.10).
One, 5 and 10 year observed survival rates were based on
187, 128 and 33 KS patients and were 0.92 (s.e.=0.02), 0.69
(s.e. =0.03) and 0.46 (s.e. =0.04) respectively. Median survival
was 9.35 years (Figure 1). On account of the higher average
age of the study population, relative survival rates were close
to unity, i.e. 0.97 (s.e. =0.02), 0.89 (s.e. =0.04) and 0.83
(s.e. =0.08).
The observed survival curve in women was super-
imposable on the one in men (death HR= 1.08, 95%
CI =0.70- 1.68) KS patients aged 65-74 years and 75
years or more showed significantly lower survival rates
than those aged 50-64 (death HR=3.37, 95% CI=1.63-
6.98 and death HR=6.51, 95% CI=3.15-13.47, respec-
tively) (data not shown). KS patients whose lesions were
restricted to lower limbs had an HR of 1.02 (95%
CI=0.67-1.54) compared with those with involvement of
other anatomical sites (Figure 1). After allowance for age
and sex, however, involvement of site(s) other than lower
limbs showed a somewhat higher death risk (HR= 1.32,
95% CI=0.85-2.04).
In order to examine the risk of second primary cancer
Table I Distribution of 204 cases of classic Kaposi's sarcoma by
age, tumour site and sex (Italy, 1976-91)
Males Females
n (%) n (%)
Age (years)
50-64 38 (27) 13 (20)
65-74 60 (43) 25 (38)
>75 41 (30) 27 (42)
Site
Lower limbs 74 (53) 48 (74)
Other 65 (47) 17 (26)
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Figure 1 Observed cumulative survival rates overall (a), and by
sex (b) and site(s) (c) in 204 patients with classic Kaposi's
sarcoma. Italy, 1976-91.
after classic KS, we identified all metachronous cancer
diagnoses (i.e. all those made more than 2 months after
primary KS). The expected number of cancers was based on
sex, age quinquennium and calender year-specific incidence
rates in all 11 cancer registries and the number of person-
years at risk in each group (Breslow and Day, 1987). Eleven
new primaries were reported. The majority (seven cancers)
emerged in the first 2 years after KS diagnosis. Cancer of
the lung and kidney were each diagnosed in two men. Other
second primaries in men included bladder, stomach, multiple
myeloma and skin (non-melanomatous). In women, one case
of cancer of the breast, one basal cell carcinoma and one
cutaneous malignant melanoma were diagnosed. For all
cancers the expected number in KS patients was 12, i.e. not
different from the observed number.
Discussion
Our study has some limitations in that we lacked complete
information on the clinical and histological characteristics of
examined KS patients (stage, treatment(s), etc). We are also
aware that it is impossible to establish accurately the date of
onset of classic KS, on account of its indolent course.
Furthermore, the number of second primary cancers might
have been somewhat overestimated because of increased
medical surveillance after KS diagnosis, or underestimated on
account of incomplete cancer registration. Finally, because of
the rarity of classic KS, survival rates and number of second
primaries have wide confidence intervals.
Despite this, the present Italian series of classic KS cases,
in which AIDS could be confidently excluded offered an
important opportunity to study an unselected series of such a
rare disease. The chronic course of classic KS is thus
confirmed. In agreement with the lack of prognostic
advantage observed in women with African KS (Templeton
and Bhana, 1975), survival was similar in the two sexes. This
does not lend support to the theory according to which
human chorionic gonadotropin and other hormones of the
same family (which are also present outside pregnancy and in
post-menopausal women) may exert some control over
neovascularisation and KS growth (Harris, 1995; Lunardi-
Iskandar et al., 1995).
In addition to showing a substantially longer survival,
patients with classic KS differ from patients with AIDS-
related KS in that there is no clear association with second
primaries, including NHL. As a considerable overlap exists
between different KS types with respect to histological and
immunohistochemical properties and possibly aetiology
(Franceschi and Geddes, 1995) our data may suggest that
cancer excess following AIDS-related KS should be mainly or
exclusively attributed to immune system impairment in AIDS
patients.
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